Astragalus Injection for Hypertensive Renal Damage: A Systematic Review

Table 2

The Analysis of Improvement of renal damage indices.

Renal damage indices and comparison between the groups	No. of studies	WMD [95% CI]	𝑃 value
β 2-MG
Astragalus versus glucose injection [10]	1	−15.14 [−21.61, −8.67]	𝑃<0.00001
mAlb
Astragalus versus glucose injection [10]	1	−28.4 [−47.67, −9.15]	𝑃=0.004
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]	1	−4.20 [−7.47, −0.93]	𝑃=0.01
eGFR
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]	1	4.10 [−2.38, 10.58]	𝑃=0.21
pulse pressure
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]	1	−7.00 [−11.56, −2.44]	𝑃=0.003
SBP
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]	1	−21.70 [−31.24, −12.16]	𝑃<0.00001
DBP
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]	1	−4.20 [−11.02, 2.62]	𝑃=0.23
serum potassium
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]	1	−0.08[−0.28, 0.12]	𝑃=0.44
twenty-four hours urinary protein content
Astragalus plus Telmisartan, Plendil versus Telmisartan, and Plendil [11]	1	−0.05 [−0.07, −0.04]	𝑃<0.00001
Astragalus plus Lotensin, Plendil versus Lotensin, and Plendil [13]	1	−0.21 [−0.50, 0.08]	𝑃=0.15
BUN
Astragalus versus prostaglandin [12]	1	−7.39 [−9.83, −4.95]	𝑃<0.00001
Scr
Astragalus versus prostaglandin [12]	1	−3.37 [46.05, 39.31]	𝑃=0.88
Ccr
Astragalus versus prostaglandin [12]	1	6.84 [4.57, 9.11]	𝑃<0.00001